Invent Medic Sweden (IMS) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
24 Oct, 2025Executive summary
Achieved strong third quarter with over 20% revenue growth year-over-year and significant improvement in profitability, moving closer to break-even.
Focused on growth through existing products in key markets and strengthened international expansion, including record orders and new distribution agreements.
Financial highlights
Q3 2025 net revenue was 1,818 KSEK, up from 1,482 KSEK in Q3 2024.
Result before tax improved to -1,149 KSEK from -1,602 KSEK year-over-year for the quarter.
EPS for Q3 was -0.01 SEK, compared to -0.04 SEK in Q3 2024.
For Jan–Sep 2025, net revenue reached 5,648 KSEK (5,289 KSEK in 2024), and result before tax was -4,088 KSEK (-5,194 KSEK in 2024).
Cash and cash equivalents at period end were 909 KSEK (1,031 KSEK in 2024).
Outlook and guidance
Positioned for continued growth with a customer-focused and efficient organization.
Ongoing commercial transformation and international expansion expected to drive further revenue and margin improvements.
Latest events from Invent Medic Sweden
- Record sales, improved results, and first positive cash flow mark progress toward profitability.IMS
Q1 2026 - Improved margins and reduced losses set the stage for profitable growth after a SEK 2.3M share issue.IMS
Q4 2025 - Net loss reduced, equity ratio strengthened, and Efemia sales surged in key European markets.IMS
Q2 2025 - Q3 sales up 63% year-over-year; rights issue boosts growth and financial strength.IMS
Q3 2024 - Efemia sales up 40% in H1 2024, narrowing losses but more capital needed for growth.IMS
Q2 2024 - Sales and financials improved, with new partnerships and equity strengthening.IMS
Q1 2025 - Efemia sales surged and capital raises position Invent Medic for break-even in 2025.IMS
Q4 2024